In partnership with

Anna's Daybreak News

_{Just facts, you think for yourself}

Tuesday, 5:17 AM

February 10, 2026

Good morning news friend! Discover today’s defining stories and the future they set in motion. 📰🌟

Notice: If you’re reading this email in the Gmail app, you will not be able to see both of our health articles at the bottom. 👉 Click here to view the full newsletter online — it’s free and easy to read.

Homebuying Ban Roadblocks

President Trump’s proposed ban on Wall Street investors buying single-family homes faces opposition in Congress amid a housing crisis marked by a 30-year low in home sales and a 50% price rise since 2019.

Congress favors supply-side measures like easing construction approvals, fearing the ban could undermine bipartisan housing legislation. Republicans question the ban’s definitions, fearing impacts on smaller landlords and investors, and prioritize free-market principles.

Trump issued an executive order restricting large investor home purchases and urged Congress to legislate the ban, but GOP leaders hesitate.

Some lawmakers support regulation of corporate landlords, while others worry about investor backlash. Housing affordability remains unresolved amid differing policy approaches.

Sources: WallStreetJournal, Investmentnews, Businessreport

Google’s 100-Year Bonds

Alphabet raised $20 billion in its largest US dollar bond sale, exceeding a $15 billion target with $140 billion in orders.

The company issued debut bonds in Switzerland and the UK, including rare 100-year UK bonds. Alphabet plans $185 billion in 2026 capital expenditure, focused on AI infrastructure and data centers, surpassing spending over the past three years.

Its long-term debt jumped to $46.5 billion in 2025, while cash reserves stood at $126.8 billion. Big Tech firms, including Amazon, Meta, and Microsoft, are forecast to spend $650 billion on capex in 2026.

Hyperscaler borrowing may hit $400 billion, pushing high-grade bond issuance to a record $2.25 trillion.

Sources: Bloomberg, Afr, FinancialTimes.

Climate Regulation Repeal

President Trump plans to repeal a 2009 climate regulation linking greenhouse gases to public health risks.

The administration argues the rule hampers economic growth and seeks to ease restrictions on energy and manufacturing industries.

This repeal represents a rollback in U.S. climate policy and aligns with Trump's broader agenda to reduce federal regulations.

The change will affect how the federal government addresses climate change, potentially reshaping environmental and economic policies in coming years.

Sources: Usnews

Weight-Loss Drug Wars

Novo Nordisk sued Hims & Hers on patent infringement for selling unapproved compounded versions of Wegovy, seeking a permanent ban and damages.

Hims planned a $49/month copycat Wegovy pill, undercutting Novo’s $149/month price, but halted sales after FDA warnings. About 1.5 million Americans use compounded GLP-1 drugs like semaglutide, which lack FDA approval.

The FDA and Health and Human Services referred Hims to the DOJ for mass marketing violations and plan further enforcement. Novo opposes large-scale compounding, arguing Wegovy is no longer in shortage.

Hims calls the lawsuit an attack on affordable care. Novo has filed around 130 such lawsuits, escalating legal battles in the $70 billion obesity drug market.

Sources: CNBC, FinancialTimes, Bloomberg, WallStreetJournal.

Neutrophils Fuel Cancer Growth

New research shows neutrophils, immune cells meant to fight disease, can promote tumor growth by producing the chemical CCL3 within tumors. Tumors reprogram neutrophils to support cancer expansion.

When neutrophils cannot produce CCL3, they still reach tumors but do not aid growth. Using genetic and bioinformatics tools, researchers specifically controlled CCL3 in neutrophils and confirmed its presence across many cancer types.

CCL3 levels in neutrophils could predict tumor progression. Blocking neutrophil-produced CCL3 offers a potential new strategy for cancer treatment by preventing immune cells from aiding tumors.

Sources: SciTechDaily

Cutting Crohn’s Symptoms

A 12-week trial withoverweight Crohn’s patients tested time-restricted feeding (TRF), requiring meals within an 8-hour window and fasting for 16 hours.

Twenty participants followed TRF; 15 maintained usual diets. TRF reduced disease activity by 40% and halved abdominal discomfort without calorie or diet changes.

TRF group lost 5.5 pounds on average, while controls gained 3.7 pounds. Blood tests showed lower inflammation markers (leptin, PAI-1), reduced visceral fat, and improved metabolism and immune function.

Researchers suggest TRF may enhance gut health and support remission. Experts recommend consulting doctors before starting TRF. Further studies are needed to confirm long-term safety and effects across diverse patients.

Sources: SciTechDaily

“You don't want to use a cannon to kill a mosquito, nor call on a Senator to help you get a dog license. Influence is a scarce article, and you shouldn't be spending it like it was Confederate money. The big guns are for the big battles.”

Baked with love,

Anna Eisenberg ❤️